atepeq/tico19 huggingface dataset:
Rates of cardiovascular symptoms is high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injury may also be related to ACE2 receptors in the heart.
ናይ ካርድዮቫስኩላር ምልክታት ንጽጽራዊ መጠን ልዑል እዩ፣ እዚ ድማ ብምኽኒያት ኣብ ናይ እዚ ሕማም ከይዲ ዝህሉ ስርዓታዊ ናይ ረኽሲ መልሲን ናይ ሕማም ምክልኻል ዓቕሚ ስርዓትን ጸገምን እዩ፣ እንተኾነ ግን ሓድሽ ማይካርዲያል ጉድኣት ምስ ናይ ልቢ ACE2 ተቐበልቲ ምኽንያት ክኸውን ይኽእል እዩ።
ACE2 receptors are highly expressed in the heart and are involved in heart function.
ናይ ACE2 ተቐበልቲ ኣብ ልቢ ብዙሓት እዮም ምስ ናይ ልቢ ስራሕ ድማ ዝተተሓሓዙ እዮም።
A high incidence of thrombosis (31%) and venous thromboembolism (25%) have been found in ICU patients with COVID-19 infections and may be related to poor prognosis.Autopsies of people who died of COVID-19 have found diffuse alveolar damage (DAD), and lymphocyte-containing inflammatory infiltrates within the lung.
ልዑል ናይ ደም ምርጋእ ኣጋጣሚ (31%) ናይ ቬነስ ደም ምርጋእ (25%) ኣብ ናይ ICU ናይ ኮቪደ-19 ሕሙማት ተረኺቡ እዩ እዚ ዳማ ምስ ድኹም ናይ ትንበያ ተኽእሎ ክተሓሓዝ ይኽእል እዩ። ብኮቪድ-19 ምኽንያት ናይ ዝሞቱ ሰባት ሬሳ ምርመራ ዲፊዩዝ ኣሊቮላር ጉድኣት (DAD)፣ ከምኡውን ኣብ ውሽጢ እቲ ሳንባ ሊምፎሳይታት ዝሓዙ ናይ ቁጥዐ ነዃላት ተረኺቦም እዮም።
Although SARS-COV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, patients with severe COVID-19 have symptoms of systemic hyperinflammation.
SARS-COV-2 ን ACE2-ንናይ ስርዓተ ምስትንፋስ ኢፒተልያል ዋህዮታት ዝገልጽ ትሮፒዝም ኣለዎ፣ ከቢድ ኮቪድ-19 ዘለዎም ሰባት ናይ ስርዓታዊ ሃይፐርኢንፍላሜሽን ምልክታት ኣለውዎም።
In particular, pathogenic GM-CSF-secreting T-cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in COVID-19 patients.
ብፍላይ፣ ኣብ ናይ ኮቪድ-19 ዝሓመሙ ከቢድ ናይ ሳንባ ፓቶሎጂ ዘለዎም ሰባት፣ ሕማም ዘስዕቡ GM-CSF-መምረቲ T-cells ምስ ናይ ኢንፍላማቶሪ IL-6-መምረቲ ሞኖሳይታት ክተሓባበሩ ተራእዮም እዮም ።
Lymphocytic infiltrates have also been reported at autopsy.
ሊምፎሳይቲክ ኢንፍልትሬት ኣብ ናይ ሬሳ ምርመራ ክርከቡ ክኢሎም እዮም።
The WHO has published several testing protocols for the disease.
WHO ዝተፈላለዩ ናይ እዚ ሕማም ናይ ምርመራ ፕሮቶኮላት ኣሐቲሙ ኣሎ።
The standard method of testing is real-time reverse transcription polymerase chain reaction (rRT-PCR).
እቲ ደረጃኡ ዝሓለወ ናይ ምርመራ መንገዲ real-time reverse transcription polymerase chain reaction (rRT-PCR)እዩ።
The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used.
እዚ ምርመራ ኣብ ናይ መተንፈሲ ናሙናታት ብ ናዞፋሪንጃል ስዋብ ዝካየድ እዩ; እንተኾነ ግን ናይ ኣፍንጫ ስዋብ ወይ ዓኽታ እውን ምጥቃም ይከአል እዩ።
Results are generally available within a few hours to two days.
ውጽኢታት ብሓፈሻ ኣብ ውሽጢ ዝተወሰኑ ሰዓታት ክሳብ ክልተ መዓልቲታት ምርካብ ይከኣል።
Blood tests can be used, but these require two blood samples taken two weeks apart and the results have little immediate value.
ናይ ደም ምርመራታት ምጥቃም ይከኣል፣ እዚ ግን ክልተ ናይ ደም ናሙናታት በቢ ክልተ ሰሙን ኣፈላላይ ክውሰዱ ይሓትት፣ ድማ ውጽኢታት ድማ ቅልጡፍ ዝኾነ ዋጋ ዳርጋ የብሎምን።
Chinese scientists were able to isolate a strain of the coronavirus and publish the genetic sequence so laboratories across the world could independently develop polymerase chain reaction (PCR) tests to detect infection by the virus.
ናይ ቻይና ሳይንቲስታት ናይ እቲ ኮሮናቫይረስ ስተረይን ክፈልዩን ናይ ጀነቲክ ተኸታታልነት ከሐትሙን ክኢሎም እዮም፣ በዚድማ ኣብ ዓለም ዘለዉ ቤት ፈተነታት ኩሎም ዓርሶም ክኢሎም ነቶም በቲ ቫይረስ ዝመጽእ ረኽሲ ንምልላይ ዝግበሩ ናይ polymerase chain reaction (PCR)( ፖሊመሬዝ ሰንሰለታዊ ምውሃድ) ፈተነታት ንኸካይዱ እዩ።
As of 4 April 2020, antibody tests (which may detect active infections and whether a person had been infected in the past) were in development, but not yet widely used.
ካብ 4 ኣፕሪል 2020 ጀሚሩ፣ ናይ ኣንቲቦዲታት ምርመራ (ንጡፋት ረኽሲታት ከለሊ ይኽእል እቲ ሰብ ድማ ቅድሚ ሕዚ ተለኺፉ ምንባሩ ንፍላጥ የኽእል) ኣብ ምዕባለ ኔሮም፣ ብሰፊሑ ግን ኣብ ጥቕሚ ኣይወዓሉን።
The Chinese experience with testing has shown the accuracy is only 60 to 70%.
ናይ ቻይና ናይ ምርመራ ተሞክሮ እቲ ትኽክለኝነት ካብ 60 ክሳብ 70% ከምዝኾነ ኣርእዩ።
The FDA in the United States approved the first point-of-care test on 21 March 2020 for use at the end of that month.Diagnostic guidelines released by Zhongnan Hospital of Wuhan University suggested methods for detecting infections based upon clinical features and epidemiological risk.
ኣብ ኣሜሪካ ዘሎ FDA ነቲ ናይ መጀመርታ ናይ ምርመራ ነጥቢ ኣብ 21 ማርች 2020 ኣብቲ ወርሒ መወዳእታ ኣብ ጥቕሚ ንክውዕል ፈቒዱ። ናይ ምርመራ መምርሒታት ብናይ ውሃን ዩኒቨርሲቲ ጆንግናን ሆስፒታል ብክሊኒካላዊ ባህርያታትን ኢፒደሞሎጂካል ሓደጋታትን ረኽሲታት ናይ ምርካብ ሓሳብ ኣቕሪቦም።
Bilateral multilobar ground-glass opacities with a peripheral, asymmetric and posterior distribution are common in early infection.
ክልተኣዊ ማልቲሎባር ሳዕሪ ዝመስሉ ፐሪፈራል፣ ኣሲመትሪክን ዳሕረዋይን ዝርጋሐ ኣብ ናይ መጀመርያታት ረኽሲ ልሙድ እዩ።
Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses.
ሳብፕሉራል ዓብላሊነት፣ crazy paving (ናይ lobular septal(ሎቡላር ሴፕታል) ምሕፋስ ምስ ተለዋዋጢ ናይ alveolar(ኣልቪዮላር) ምምላእ)፣ እቲ ሕማም እንዳበኣሰ ክኸይድ እንከሎ ቁሳዊ ጥማር እውን ክፈጠር ይኽእል እዩ።
Few data are available about microscopic lesions and the pathophysiology of COVID-19.
ብዛዕባ ማይሮስኮፒክ ቁስሊታትን ናይ ኮቪድ-19 ፓቶፊዝዮሎጂ ዝተወሰኑ ዳታታት ኣለዉ።
The main pathological findings at autopsy are:
ኣብ ናይ ሬሳ ምርመራ ዋና ፓታሎጂካዊ ርካቦታት:
Macroscopy: pleurisy, pericarditis, lung consolidation and pulmonary oedema
ማክሮስኮፒ፡ ፐሉሪሲ፣ ፔሪካርዳይትስ፣ ናይ ሳንባ ኮንሲዲሌሽንን ፑሉሙናሪ ሕብጠትን
Four types of severity of viral pneumonia can be observed:
ኣርባዕተ ዓይነት ናይ ቫይረስ ኒዩሞንያ ከቢድነት ምርኣይ ይከኣል:
mild pneumonia: pulmonary oedema, pneumocyte hyperplasia, large atypical pneumocytes, interstitial inflammation with lymphocytic infiltration and multinucleated giant cell formation
ቀሊል ናይ ሳንቡእ ወቕዒ: ናይ ፑልሙኒሪ ኢዴማ፣ ኒሞሳይት ሃይፐርፕላዠያ፣ ዓብዪ ኤታይፒካል ኒሞሳይታት፣ ኢንተርስቲሻል ቁጥዐ ምስ ሊምፎሳይቲክ ኢንፍልትሬሸንን ማልቲኒኩሌትድ ዓበይቲ ዋህዮታትን
severe pneumonia: diffuse alveolar damage (DAD) with diffuse alveolar exudates.
ከቢድ ናይ ሳንቡእ ወቕዒ፣ ዲፊዩዝ ኣልቪዮላር ጉድኣት (DAD) ምስ ዲዩዝ ኣልቪዮላር ኤክሱዴት።
DAD is the cause of acute respiratory distress syndrome (ARDS) and severe hypoxemia.
DAD ብህጹጽ ናይ ስርዓተ ምስትንፋስ ምውዳቕ ሲንድረምን (ARDS) ከቢድ ሃይፖክሲምያን ዘምጽእ እዩ።
healing pneumonia: organisation of exudates in alveolar cavities and pulmonary interstitial fibrosis
ዝሓዊ ዘሎ ናይ ሳንቡእ ወቕዒ፣ ኣብ ኣልቪዮላር በእታትን ፑልሙናሪ ኢንተርስቲሽያል ፋይብሮሲስ ፈሰስቲ ምእካብ
Blood: disseminated intravascular coagulation (DIC); leukoerythroblastic reaction
ደም: ዝተበተነ ኢንትራቫስኩላር ምርጋእ (DIC); ሊኮኢሪትሮብላስቲክ ውህደት
Preventive measures to reduce the chances of infection include staying at home, avoiding crowded places, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene and avoiding touching the eyes, nose or mouth with unwashed hands.
ናይ ምልካፍ ዕድል ዝቕንሱ መከላኸሊ መገዲታት ኣብ ገዛኻ ምጽናሕ፣ ሰብ ዝበዝሖም ቦታታት ምውጋድ፣ ኣእዳው ብሳሙናን ማይን እንተንኢሱ ን 20 ሰከንድታት ምሕጻብ፣ ጽቡቕ ናይ ስርዓት ምስትንፋስ ጽሬት ብምሕላውን ዓይኒ፣ ኣፍንጫ ወይ ኣፍ ምንካእ ምውጋድን ዘተቓልል እዩ።
The CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available.
CDC ክትስዕሉ ወይ ክትህንጥሱ ከለኹም ኣፍኩም ብሶፍት ምሽፋንን ሶፍት እንተዘይሃሊኩም ድማ ኩርናዕ ኢድኩም ክትጥቀሙ ይመክር።
Proper hand hygiene after any cough or sneeze is encouraged.
ግቡእ ናይ ኢድ ጽሬት ድሕሪ ምስዓል ወይ ምህንጣስ ዝበረታታዕ እዩ።
The CDC has recommended the use of cloth face coverings in public settings, in part to limit transmission by asymptomatic individuals.Social distancing strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel and cancelling large public gatherings.
CDC ምልክት ካብ ዘየርእዩ ሰባት ናይ ምምሕልላፍ ክእለት ንምግታእ፣ ብዙሕ ሰብ ኣብ ዘለዎ ቦታ ናይ ገጽ መሸፈኒ ምጥቃም ይመክር። ናይ ማሕበራዊ ርሕቐት ሜላታት ጉዕዞታት ብምግዳብን ናይ ብዙሕ ሰብ ምእካብ ዘለዎ ቦታታት ብምዕጻውን፣ ዝተለኸፉ ሰባት ምስ ብዙሓት ሰባት ንከይራኸቡ ቤት ትምህርቲታትን ናይ ስራሕ ቦታታትን ብምዕጻው ዝተገበሩ እዮም።
Distancing guidelines also include that people stay at least 6 feet (1.8 m) apart.
ናይ ርሕቐት ምሕላው መምርሒታት ሰባት እንተንኢሱ 6 ጫማ (1.8 ሜ) ክረሓሓቑ ኣለዎም።
There is no medication known to be effective at preventing COVID-19.As a vaccine is not expected until 2021 at the earliest, a key part of managing COVID-19 is trying to decrease the epidemic peak, known as "flattening the curve".
ኮቪድ -19 ንምክልኻል ብቑዕ ዝኾነ መድሓት የለን። ከትባት ድማ ዝቐረበ ተባሂሉ ክሳብ 2021 ትጽቢት ኣይግበሮን፣ ናይ ኮቪድ-19 ምቁጽጻር ቁልፊ ሜላ ናይ እዚ ለበዳ ጫፍ ምውራድ እዩ እዚ ድማ፣ "ነቲ ከርቭ ፍላት ምግባር "ይበሃል።
The CDC also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose, coughing or sneezing.
CDC ውልቀ ሰባት በተደጋጋሚ እንተንኢሱ ን 20 ሰከንድታት ኢዶም ክሕጸቡ ይመክር፣ ብፍላይ ድሕሪ ናብ ሽንቲ ቤት ምኻድኩም ወይ ኣእዳውኩም ዝረአ ርስሓት እንተሊዎ፣ ቅድሚ ምብላዕ ወይ ድሕሪ ኣፍንጫኹም ምንፋጥኩም፣ እንተስዒልኩም ወይ እንተሀንጢስኩም።
It further recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available.For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production.
ብተወሳኺ ድማ ሳሙናን ማይን እንተዘይህሉዉሉ ግዘ ጥራይ፣ እንተንኢሱ 60% ኣልኮል ዘለዎ ሳኒታይዘር ምጥቃም ዝምከር እዩ።ንግዳዊ ናይ ኢድ ሳኒታይዘራት ኣብ ዘይርከበሉ፣ ውድብ ጥዕና ዓለም(WHO) ክልተ ንከባቢያዊ ምህርቲ መዳላዊ ዝኾኑ ቅመማታት ሂቡ ኣሎ።
In these formulations, the antimicrobial activity arises from ethanol or isopropanol.
ኣብ እዞም ሰነ-ሓሳባት እዚኦም፣ እዞም ጸረ ማይክሮቢያል ንጥፈታት ካብ ethanol ወይ isopropanol ዝመጹ እዮም።
Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis".
ምስ ኣልኮል ሃይድሮጅን ፐር ኦክሳይድ ናይ ባክቴርያ ተሃዋስያን ኣብ ምጥፋእ ይሕግዝ፤ “ንናይ ኢድ ኣንቲሰፕሲስ ንጡብ ውሁድ ኣይኮነን”
Glycerol is added as a humectant.
ግላይሴሮል ከም ሂዩመክታንት ዝተሓወሰ እዩ።
People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs.
ሰባት ሓገዝቲ ክንክናት እዮም ዝግበሩሎም፣ ናይ ፈሳሲ ሕክምና፣ ናይ ኦክሲጅን ሓገዝን ካልኦት ዝተጎድኡ ዓበይቲ ኦርጋናትን ምሕጋዝ ድማ የጠቓልል።
The CDC recommends that those who suspect they carry the virus wear a simple face mask.
CDC እቲ ቫይረስ ከምዘለዎም ዝጥርጥሩ ሰባት ማስክ ክገብሩ ኣለዎም ኢሉ።
Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration.
Extracorporeal membrane oxygenation (ECMO) ናይ ስርት ምስትንፋስ ውድቀት ኣብ ምፍታሕ ኣብ ጥቕሚ ዝወዓለ እዩ፣ ዝህቦም ጥቕሚታት ግን ክሳብ ሕዚ ኣብ ግምት ውሽጢ እናኣተዉ እዮም።
Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity.
ውልቃዊ ጽሬታትን ጥዕንኡ ዝሓለወ መነባብሮን ኣመጋግባን ናይ ሕማም ምክልኻል ዓቕሚ ንምምዕባል ዝምከሩ እዮም።
Supportive treatments may be useful in those with mild symptoms at the early stage of infection.The WHO and Chinese National Health Commission have published recommendations for taking care of people who are hospitalised with COVID-19.
ሓገዝቲ ሕክምናታት ቀለልቲ ምልክታት ኣብ ዘለዎም ሰባት ኣብ ናይ መጀመርያታት ምልክታት እዮም ዝጠቕሙ። WHO ን ናይ ቻይና ብሄራዊ ጥዕና ኮሚሸንን ብኮቪድ-19 ኣብ ሆስፒታል ናይ ዝደቀሱ ሰባት መተሓመሚ መምርሒታት ኣሐቲሞም።
Intensivists and pulmonologists in the U.S. have compiled treatment recommendations from various agencies into a free resource, the IBCC.
ኣብ ኣሜሪካ ዝርከቡ ተመራመርቲ ሕክምና ካብ ዝተፈላለዩ ምንጪታት ዝረኽብዎም ሓበሬታታትን ምኽርታትን ናብ IBCC ብምጥርቓም ብነጻ የቕርቡ።
As of April 2020, there is no specific treatment for COVID-19.
ክሳብ ኣፕሪል 2020 ፣ ንኮቪድ-19 ዝኸውን መድሓኒት የለን።
For symptoms, some medical professionals recommend paracetamol (acetaminophen) over ibuprofen for first-line use.
ንምልክታት፣ ገለ ናይ ሕክምና ሰብ ሞያታት paracetamol (acetaminophen) ኣብ ልዕሊ ibuprofen ከም ናይ መጀመርያ መጥቀሚ መሰመር ገይሮም ይመኽሩ።
Precautions must be taken to minimise the risk of virus transmission, especially in healthcare settings when performing procedures that can generate aerosols, such as intubation or hand ventilation.
ብፍላይ ከም ኢንቲቤሽን ወይ ናይ ኢድ ቬንትሌሽን ዝበሉ ኣብ ናይ ጥዕና ክንክን መሰናድኦ ኤሮሶላት ክፈርዩ ዝኽእሉ ከይዲታት ኣብ ዝስረሐሎም እዋናት ናይ እቲ ቫይረስ ምምሕልላፍ ዓቕሚ ንምቕናስ ቅድመ ጥንቃቐታት ክውሰዱ ኣለዎም ።
For healthcare professionals caring for people with COVID-19, the CDC recommends placing the person in an Airborne Infection Isolation Room (AIIR) in addition to using standard precautions, contact precautions and airborne precautions.The CDC outlines the guidelines for the use of personal protective equipment (PPE) during the pandemic.
ነቶም ናይ ኮቪድ-19 ዘለዎም ሰባት ዝከናኸኑ ናይ ጥዕና ሰብ ሞያታት፣ እቲ CDC ነቲ ዝሓመመ ሰብ ደረጃ ጽሬት ጥንቃቐታት፣ ናይ ኽንክን ጥንቃቐታትን ናይ ብኣየር ምምሕልላፍ ጥንቃቐታትን ምስ ምጥቃም ብተወሳኺ ኣብ ናይ ብኣየር ዝመሓላለፉ ረኽሲታት መፍለዪ ክፍሊ (AIIR) ከእትውዎ ይመክር። እዚ CDC ኣብ እዚ ናይ እዚ ለበዳ ግዘ እዚ ናይ ውልቃዊ መከላኸሊ ናውቲ (PPE) ኣጠቓቕማ መምርሒ ኣውጺኡ እዩ።
The recommended gear is: PPE gown, respirator or facemask, eye protection, and medical gloves.When available, respirators (instead of facemasks) are preferred.
እቲ ዝምክር ናይ ዓርሰ ምክልኻል ዕጥቂ: PPE ጋውን፣ መተንፈሲ ወይ ናይ ገጽ ማስክ፣ ናይ ዓይኒ መከለኸሊን ናይ ሕክምና ጓንቲታትን እዮም። ቅሩባት እንተኾይኖም፣ መተንፈሲታት (ኣብ ክንዲ ናይ ገጽ ማስክታት) ይምረጹ።
N95 respirators are approved for industrial settings but the FDA has authorised the masks for use under an Emergency Use Authorisation (EUA).
N95 መተንፈሲታት ንኢንዳስትራያል መሰናድኦ ፈቓድ ረኺቦም እዮም ግን FDA እዞም ማስክታት ኣብ ሃንደበታዊ ናይ ፈቓድ ምጥቃም (EUA) ኣብ ጥቕሚ ክውዕሉ እዩ ዝፈቅድ።
They are designed to protect from airborne particles like dust but effectiveness against a specific biological agent is not guaranteed for off-label uses.
እዚኦም ካብ ከም ኣቦራ ዝበሉ ናይ ብኣየር ዝመሓላለፉ ንጥረ ነገራ ንክከላኸሉ ተባሂሎም ዝተነደፉ እዮም፣ ይኹን ደኣምበር፣ ኣብ ዝተወሰኑ ስነ-ሂወታውያን ኤጀንታት ንምጥቃም ዘኽእል ውሕስና የብሎምን።
When masks are not available, the CDC recommends using face shields or, as a last resort, homemade masks.
ማስክ ዘይርከበሉ ግዘ፣ CDC ናይ ገጽ መከላኸሊ ወይ፣ ከም ናይ መወዳእታ መማረጺ ድማ ኣብ ገዛ ዝተሰርሑ ማስክታት ክትጥቀሙ ይመክር።
Most cases of COVID-19 are not severe enough to require mechanical ventilation or alternatives, but a percentage of cases are.
መብዛሕትኦም ናይ ኮቪድ-19 ጉዳያት ለበዳ ሜካኒካዊ ቬንትሌሽን ወይ ካልእ መማረጺ ክሳብ ዘድሊ ከበድቲ ኣይኮኑን፣ ዝተወሰኑ ክፋላት ናይ እዞም ጉዳያት ለበዳ ግን ዝደልዩ እዮም።
The type of respiratory support for individuals with COVID-19 related respiratory failure is being actively studied for people in hospital, with some evidence that intubation can be avoided with a high flow nasal cannula or bi-level positive airway pressure.
ንኮቪድ-19 ዘለዎም ናይ ስርዓተ ምስትፋስ ውድቀት ዘጋጥሞም ሰባት ዘድልዮም ናይ ምስትንፋስ ሓገዝ ኣብ ሆስፒታል ንዘለዉ ሰባት ብንጥፈት እንዳተጸንዐ ይርከብ፣ ኢንቱቤሽን ንምውጋድ ብልዑል ፍሰት ዘለዎ ናይ ኣፍንጫ ካኑላ ወይ bi-level ፖዘቲቭ ናይ ኣየር መተንፈሲ ጸቕጢ ምውጋድ ይከኣል።
Whether either of these two leads to the same benefit for people who are critically ill is not known.
ካብ እዞም ክልተ እዚኦም ንኣዝዮም ዝሓመሙ ሰባት ናብ ተመሳሳሊ ረብሓ ዘምርሑ እንተኾይኖም ክሳብ ሕዚ ኣይተፈለጠን።
Some doctors prefer staying with invasive mechanical ventilation when available because this technique limits the spread of aerosol particles compared to a high flow nasal cannula.Severe cases are most common in older adults (those older than 60 years, and especially those older than 80 years).
ገለ ዶክተራት ኢንቫሲቭ ሜካኒካል ቬንትሌሽን ምጥቃም ይመርጹ ቅሩባት እንተኾይኖም ምኽንያቱ እዚ ሜላ እዚ ምስ ልዑል ናይ ኣፈንጫ ውሕዘት ካኑላ ክነጻጸር ከሎ ናይ ኢሮሶል ንጥረ ነገራት ምስርጫው ስለዝቕንስ። ከበድቲ ጉዳያት ለበዳ ኣብ ዕድምኦም ዝደፍኡ ሰባት(ልዕሊ 60 ዓመቶም ኣብ ዝኾኑ፣ ብፍላይ ድማ ኣብ ልዕሊ 80 ዓመቶም ሰባት) እዩ መብዛሕትኡ ዝፍጠር ።
Many developed countries do not have enough hospital beds per capita, which limits a health system's capacity to handle a sudden spike in the number of COVID-19 cases severe enough to require hospitalisation.
ብዙሓት ዝማዕበሉ ሃገራት ንሕድሕድ ሕሙም እኹል ዝኾነ ናይ ሆስፒታል ዓራት የብሎምን፣ እዚ ድማ ንናይ እቲ ሕክምና ስርዓት ዓቕሚ ብኮቪድ -19 ጉዳያት ለበዳ ንዝፍጠሩ ከበድቲ ጉዳያት መከናኸኒ ዓቕሙ ክወድቕ ዝገብሮ እዩ።
One study in China found 5% were admitted to intensive care units, 2.3% needed mechanical support of ventilation, and 1.4% died.
ሓደ ኣብ ቻይና ዝተኻየደ መጽናዕቲ ከምዝረኸቦ 5% ናብ ጽዑቕ ክትትል ዩኒት ኣትዮም፣ 2.3% ሜካኒካል ናይ ምስትንፋስ ሓገዝ የድልዮም ኔሩ፣ 1.4% ድማ ሞይቶም እዮም።
In China, approximately 30% of people in hospital with COVID-19 are eventually admitted to ICU.
ኣብ ቻይና፣ ዳርጋ 30% ዝኾኑ ብኮቪድ-19 ምኽንያት ኣብ ሆስፒታል ዝነበሩ ሰባት ቀስ እንዳበሉ ናብ ICU ኣትዮም እዮም።
Mechanical ventilation becomes more complex as acute respiratory distress syndrome (ARDS) develops in COVID-19 and oxygenation becomes increasingly difficult.
ሜካኒካዊ ቬንትሌሽን ኣብ ኮቪድ-19 ህጹጽ ናይ ስርዓተ ምስትንፋስ ዲስትረስ ሲንድረም (ARDS) ክምዕብል ከሎ ውስብስብ ይኸውን ኦክሲጅኔሽን እውን ኣዝዩ ከቢድ ይኸውን።
Ventilators capable of pressure control modes and high PEEP are needed to maximise oxygen delivery while minimising the risk of ventilator-associated lung injury and pneumothorax.
ናይ ጸቕጢ ቁጽጽርን ልዑል PEEP ዘለዎም ቨንቲሌተራት ናይ ኦክሲጅን ምብጽጻሕ ብምውሳኽ ምስ ቬንትሌተር ዝተተሓሓዙ ናይ ሳንባ ጉድኣታትን ኒሞቶራክስን ዝቕንሱ እዮም።
High PEEP may not be available on older ventilators.
ልዑል PEEP ኣብ ናይ ቀደም ቨንቲሌተራት ዘይክህሉ ይኽእል።
Research into potential treatments started in January 2020, and several antiviral drugs are in clinical trials.
ኣብቶም ክህልዉ ዝኽእሉ ሕክምናታት ዝግበር መጽናዕቲ ኣብ ጃንዋሪ 2020 ተጀሚሩ፣ ዝተፈላለዩ ጸረ ቫይረስ መድሓታት ድማ ኣብ ክሊኒካላዊ ፈተነታት ይርከቡ።
Remdesivir appears to be the most promising.
Remdesivir(ረምድስቪር) ዝሓሸ ተስፋ ወሃቢ ኮይኑ ተረኺቡ ኣሎ።
Although new medications may take until 2021 to develop, several of the medications being tested are already approved for other uses or are already in advanced testing.
ዋላ ሓደሽቲ መድሓኒታት ምምዕባል ክሳብ 2021 ክጸንሕ ዝኽኣሉ ይኹኑ፣ መብዛሕትኦም ዝፍተኑ ዘለዉ መድሓኒታት ግን ንካልኦት ጥቕሚታት ፈቓድ ረኺቦም ወይ ኣብ ልዑል ናይ ፈተነ ደረጃ እዮም ዘለዉ።
Antiviral medication may be tried in people with severe disease.
ጸረ ቫይረስ ሕክምና ኣብ ከቢድ ሕማም ዝተረኣዮም ውልቀ ሰባት ክፍተን ይኽእል።
The WHO recommended volunteers take part in trials of the effectiveness and safety of potential treatments.The FDA has granted temporary authorisation to convalescent plasma as an experimental treatment in cases where the person's life is seriously or immediately threatened.
ውድብ ጥዕና ዓለም(WHO) ኣብ ናይ ገለ መድሓታት ብቑዕነትን ደሕንነትን ውሕስነትን ንምርግጋጽ ኣብ ዝግበር ፈተነ ወለንታዊያን ን ክሳትፍ ሓቲቱ። FDA ንኮንቨልሰንት ፕላዝማ ናይ እቲ ሰብ ህይወት ብከቢድ ወይ ብቐጠታ ኣብ ሓደጋ ኣብ ዝኣትወሉ ግዘ ከም ናይ ፈተነ መድሓኒት ን ክኾን ግዜኣዊ ፈቓድ ሂቡ ኣሎ።
It has not undergone the clinical studies needed to show it is safe and effective for the disease.
ነቲ ሕማም ደሕንነቱ ዝሓለወን ኣድማዒን ከምዝኾነ ዘርኢ ክሊኒካላዊ መጸናዕቲ ኣይገበረን።
In February 2020, China launched a mobile app to deal with the disease outbreak.
ኣብ ፌብሩዋሪ 2020፣ ቻይና ናይ እዚ ሕማም ለበዳ ንምቁጽጻር ናይ ሞባይል መተግበሪ ኣላልያ እያ።
Users are asked to enter their name and ID number.
ተጠቀምቲ ሽሞምን ናይ ID ቁጽሮምን ከእትዉ ይሕተቱ።
The app is able to detect 'close contact' using surveillance data and therefore a potential risk of infection.
እዚ መተግበሪ ናይ ሰርቬላንስ ዳታ ብምጥቃም ናይ ረኽሱ ሓደጋ ኣጋጣሚ ክኸውን ዝኽእል ናይ 'ቀረባ ንኽክእ ' ክፈልጥ ይኽእል እዩ።
Every user can also check the status of three other users.
ሕድሕድ ተጠቃሚ ናይ ካልኦት ሰለስተ ተጠቀምቲ ኩነታት ክርኢ ይኽእል እዩ።
If a potential risk is detected, the app not only recommends self-quarantine, it also alerts local health officials.Big data analytics on cellphone data, facial recognition technology, mobile phone tracking and artificial intelligence are used to track infected people and people whom they contacted in South Korea, Taiwan and Singapore.
ሓደጋ ከስዕብ ዝኽእል ኣጋጣሚ እንተተፈጢሩ፣ እዚ መተግበሪ ዓርስኻ ምፍላይ ጥራሕ ዘይኮነ ዝመክር፣ ንከባቢያዊ ናይ ጥዕና ሰበ ስልጣናት እውን ይሕብሮም እዩ። ኣብ ደቡብ ኮርያ፣ ታይዋንን ሲንጋፖርን ኣብ ተንቀሳቓሲ ቴሌፎን ዳታ፡ናይ ገጽ መለለዪ ቴክኖሎጂ፣ ናይ ሞባይል ተሌፎን መድለዪን ኣርቴፊሻል ኢንተለጀንስን ዝርከብ ናይ ቢግ ዳታ ኣናላይቲክስ ፣ ዝተለኸፉ ሰባት ንምእላሽን ዝነኽእዎም ሰባት ንምፍላጥን ኣብ ጥቕሚ ዝውዕል እዩ።
In March 2020, the Israeli government enabled security agencies to track mobile phone data of people supposed to have coronavirus.
ኣብ ማርች 2020፣ ናይ እስራኤል መንግስቲ ናይ ደሕንነት ኤጀንሲታት ኮሮናቫይረስ ናይ ዘለዎም ሰባት ሞባይል ተሌፎን ዳታ ንኽከታተሉ ፈቒዱሎም እዩ።
The measure was taken to enforce quarantine and protect those who may come into contact with infected citizens.
እዚ ስጉምቲ ኳረንቲን ንምብርትታዕን ምስ ዝተለኸፉ ዜጋታት ዝተነኻኽኡ ሰባት ንምሕብሓን እዩ ተወሲዱ።
Also in March 2020, Deutsche Telekom shared aggregated phone location data with the German federal government agency, Robert Koch Institute, in order to research and prevent the spread of the virus.
ኣብ ማርች 2020 እውን፣ Deutsche Telekom ናይ እቲ ቫይረስ ዝርጋሐ ንምጽናዕን ንምክልኻልን፣ ሓፈሻዊ ናይ ተሌፎን ቦታታት ዳታ ንጀርመን ፌደራላዊ ኤጀንሲ፣ Robert Koch ትካል፣ ኣካፊልዎም።
Russia deployed facial recognition technology to detect quarantine breakers.
ሩስያ ኳረንቲ ሴሮም ዝወጹ ሰበት ንምልላይ ናይ ገጽ መለለዪ ቴክኖሎጂ ናብ ስራሕ ኣእቲያ ኣላ።
Italian regional health commissioner Giulio Gallera said he has been informed by mobile phone operators that "40% of people are continuing to move around anyway".
ናይ ጣልያን ክልላዊ ጥዕና ኮሚሽነር ጁሊዮ ጋሌራ ብሞባይል ተሌፎን አፕሬተራት "40% ዝኾኑ ሰባት ምንቅስቓሶም ቀጺሎም " ከምዘለዉ ከምዝተሓበረ ገሊጹ።
German government conducted a 48 hours weekend hackathon with more than 42.000 participants.
መንግስቲ ጀርመን ልዕሊ 42,000 ተሳተፍቲ ዝተዓደምሉ ናይ 48 ሰዓታት ሃካቶን ኣካይዱ።
Also the president of Estonia, Kersti Kaljulaid, made a global call for creative solutions against the spread of coronavirus.
ናይ Estonia, Kersti Kaljulaid ፕረዚዳንት፣ ኣንጻር ኮሮናይረስ ዝኸውን ዓለምለኻዊ ፈጠራዊ መፍትሒ ክፍጠር ጻውዒት የቕርቡ።
Individuals may experience distress from quarantine, travel restrictions, side effects of treatment or fear of the infection itself.
ውልቀሰባት ኣብ ኳረንቲን፣ ናይ ጉዕዞ እገዳታት፣ ጎድናዊ ጸገማትን ናይ እቲ ረኽሲ ፍርሒ ንባዕሉ ጭንቀት ከሕድረሎም ይኽእል እዩ።
BBC quoted Rory O'Connor in saying, "Increased social isolation, loneliness, health anxiety, stress and an economic downturn are a perfect storm to harm people's mental health and wellbeing."
BBC ሮርይ ኦኮኖር ኢሉዎ ኣብ ዝበሎ "ማሕበራዊ ተነጽሎ፣ ጽምዋ፣ጥዕናዊ ጭንቀት፣ ኣዕምሮኣዊ ውጥረትን ኢኮኖሚካዊ ውድቀትን እንትበዝሕ፣ ንናይ ሰባት ስነ ኣእምሮኣዊ ጥዕናን ደሕነነት ዝጎድኡ ነገራት እዮም"።
The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold.
እቲ ሕማም ካልኦት ልሙዳት ከም ሰዓል ዝበሉ ናይ ላዕለዋይ መተንፈሲ ኣካል ሕማማት ብዝምስል መልክዑ ዝተወሰኑ ምልክታት ክህልውዎ ይኽእሉ ወይ ምንም ምልክታት ዘይከርኢ ይኽእል።
Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover.
ቀለልቲ ጉዳያት ለበዳ ኣብ ውሽጢ ክልተ ሰሙናት ይሓውዩ፣ እቶም ከቢድ ወይ ኣስጋኢ ሕማም ዘለዎም ግን ንክሓውዩ ካብ ሰለስተ ክሳብ ሽድሽተ ሰሙናት ይወስደሎም እዩ።
Pregnant women may be at higher risk for severe infection with COVID-19 based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking.In some people, COVID-19 may affect the lungs causing pneumonia.
ካብ ከም SARS ን MERS ን ዝበሉ፣ ናይ ኮቪድ -19 ሓበሬታ ዝተማልእ ኣይኮነን፣ ካልኦት ተመሳሰልቲ ቫይረሳት ዝተወሰደ ሓበሬታ ከምዘርእዮ፣ ጥኑሳት ኣንስቲ ንናይ ኮቪድ-19 ከቢድ ረኽሲ ተጋለጽቲ እየን። ኣብ ገለ ሰባት፣ ኮቪድ-19 ን ሳንቡእ ብምጥቃዕ ናይ ሳንቡእ ወቕዒ ከሰዕብ ይኽእል እዩ።
In those most severely affected, COVID-19 may rapidly progress to acute respiratory distress syndrome (ARDS) causing respiratory failure, septic shock or multi-organ failure.
ኣብ እዞም ብከቢድ ዝተሃሰዩ፣ ኮቪድ-19 ብቕልጡፍ ናብ ከቢድ ናይ ስርዓተ ምትንፋስ ዲስትረስ ሲንድረም (ARDS) ብምዕባይ ናብ ናይ ስርዓተ ምስትንፋስ ውድቀት፣ ሰፕቲክ ሾክ ወይ ናብ ናይ ብዙሓት ኣካላት ሰብነት ውደቀት ከምርሕ ይኽእል እዩ።
Complications associated with COVID-19 include sepsis, abnormal clotting and damage to the heart, kidneys and liver.
እቶም ምስ ኮቪድ-19 ዝተተሓሓዙ ዝኸፍኡ ጽልዋታት ሰፕሲስ፣ ዘይስሩዕ ደም ምርጋእን ናይ ልቢ፣ ኩላሊትን ጉበትን ጉድኣትን ዝጠቓለሉ እዮም።
Clotting abnormalities, specifically an increase in prothrombin time, have been described in 6% of those admitted to hospital with COVID-19, while abnormal kidney function is seen in 4% of this group.
ናይ ደም ምርጋእ ዘይንቡር ኣጋጣሚታት፣ ብፍላይ ናይ ፕሮትሮምቢን ምውሳኽ፣ ኣብቶም ብ ኮቪድ-19 ምኽንያት ኣብ ሆስፒታል ዝደቀሱ 6% ሰባት ተራእዩ፣ ዘይንቡር ናይ ኩሊት ተግባር እውን ኣብ 4% ናይ እዞም ጉጅለ ተራእዩ እዩ።
Approximately 20-30% of people who present with COVID-19 demonstrate elevated liver enzymes (transaminases).
ዳርጋ ካብ 20-30% ዝኾኑ ብኮቪድ -19 ዝተተሓዙ ሰባት ልዑል ናይ ጸሊም ከበዲ ኤንዛይማት (ትራንሳሚኔዝ) ኣርእዮምእዮም።
According to the same report, the median time between onset of symptoms and death was ten days, with five being spent hospitalised.
ብመሰረት ተመሳሳሊ ጸብጻብ፣ ኣብ መንጎ ምልክታት ዝረኣዩሉ መዓልቲን ሞትን ዘሎ ኣፈላላይ ዓሰርተ መዓልቲ እዩ፣ ሓሙሽተ መዓልቲ ኣብ ሆስፒታል ዝጽንሑሉ መዓልቲ እዩ።
However, patients transferred to an ICU had a median time of seven days between hospitalisation and death.
እንተኾነ ግን፣ እቶም ናብ ICU ዝተዘዋወሩ ሕሙማት ካብ ኣብ ሆስፒታል ደቂሶም ምሕካም ዝጀመሩሉ ስጋብ ሞት ብማእኸላይ ሸውዓተ መዓልቲታት ኣለዎም።
In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days.
ኣብ ናይ መጀመርያታት መጽናዕቲ፣ ናይ መጀመርያ ምልክታት ድሕሪ ምርኣይ ክሳብ ሞት ዘሎ ግዘ 14 መዓልቲታት እዩ፣ ካብ ሽድሽተ ክሳብ 41 መዓልቲታት ግን ክኾን ይኽእል እዩ።
In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%.
ብ National Health Commission (NHC) (ናይ ቻይና ብሄራዊ ጥዕና ኮሚሽን) ዝተገበረ ጽንዓት፣ ሰብኡት ናይ 2.8% ናይ ሞት ንጽጽራዊ መጠን እንትህልዎም ኣንስቲ ድማ 1.7% ናይ ሞት ንጽጽራዊ መጠን እዩ ዘለወን።
Histopathological examinations of post-mortem lung samples show diffuse alveolar damage with cellular fibromyxoid exudates in both lungs.
ናይ ዝሞተ ሰብ ሳንባ ናይ ሂስቶፓቶሎጂካል ምርመራታት ናሙናታት ዲፊዩዝ ኣልቪዮላር ጉድኣት ኣብ ክልቲኦም ሳንባታት ድማ ፋይብሮሜክሶይድ ኤክሱዴታት ሒዞም ይርከቡ።
Viral cytopathic changes were observed in the pneumocytes.
ቫይራል ሳይቶ ፓቲክ ለውጢታት ኣብ ኒሞሳይታት ተራይኦም እዮም።
The lung picture resembled acute respiratory distress syndrome (ARDS).
እዚ ናይ ሳንባ ስእሊ ህጹጽ ናይ ስርዓተ ምስትንፋስ ዲስትረስ ሲንድረም (ARDS) ይመስል።
In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest.
ኣብ 11.8% ብናይ ቻይና ናይ ጥዕና ኮሚሽን ጸብጻብ ዝተገበሩ ሞታት፣ ናይ ልቢ ጉድኣት ብናይ ትሮፖኒን ምልዓል ወይ ናይ ልቢ ምዕራፍ ዝመጹ እዮም።
According to March data from the United States, 89% of those hospitalised had preexisting conditions.Availability of medical resources and the socioeconomics of a region may also affect mortality.
ካብ ሕቡራት መንግስቲታት ኣሜሪካ ዝወጹ ናይ ማርች ዳታታት ብዝብልዎ መሰረት፣ 89% እቶም ደቂሶም ዝሕከሙ ዘለዉ ሰባት ቅድሚኡ ካልእ ናይ ጥዕና ኩነታት ዝነበሮም እዮም። ናይ ሕክምናዊ ምንጪታትን ሶሽዮኢኮኖሚክ ዓቕሚን ንበዝሒ ሞት ይጸልዉ እዮም።
Estimates of the mortality from the condition vary because of those regional differences, but also because of methodological difficulties.
ብ ሰንኪ ክልላዊ ፍልልያትን ከምኡውን ብሜትዶሎጂካል ፍልልይ እዚ ናይ ዝሞቱ በዝሒ ግምታት ዝተፈላለዩ እዮም።
The under-counting of mild cases can cause the mortality rate to be overestimated.
ነቶም ቀለልቲ ጉዳያት ለበዳ ብኣግባቡ ዘይምቑጻር ናይ እቲ ናይ ሞት ንጽጽራዊ መጠን ካብ እቲ ዝተገመተ ንላዕሊ ክገብሮ ይኽእል እዩ።
However, the fact that deaths are the result of cases contracted in the past can mean the current mortality rate is underestimated.
ይኹን እምበር ሕጂ ዝረኣዩ ሞት ናይ ዝጸንሑ ሕሙማን ብምዃኖም ናይ ሕጂ መጠን ሞት ሙሉእ ብሙሉእ ኣይግልጹን
Smokers were 1.4 times more likely to have severe symptoms of COVID-19 and approximately 2.4 times more likely to require intensive care or die compared to non-smokers.Concerns have been raised about long-term sequelae of the disease.
ሽጋራ መትከኽቲ 1.4 ግዘ ከቢድ ናይ ኮቪድ-19 ምልክታት ናይ ምርኣይ ተኽእሎ ኣለዎም ዳርጋ 2.4 ግዘ ጽዑቕ ክትትል የድልዮም እዩ፣ ወይ ድማ ምስ ዘየትክኹ ክነጻጸሩ ከለዉ ክሞቱ ዝኽእሉ እዮም። ብዛዕባ ናይ ነዊሕ ግዘ ናይ እቲ ሕማም ሳዕቤን ስግኣታት ነይሮም እዮም።
The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage.
ናይ ሆንግ ኮንግ ሆስፒታላት ምምሕዳር ኣብቶም ካብ እቲ ሕማም ዝሓውዩ ሰባት 20% ክሳብ 30% ዝኸውን ናይ ሳንባ ዓቕሚ ምውራድ ረኺቡ፣ ናይ ሳንባ ስካናት ድማ ናይ ሰብነት ኣካላት ዕንወት ኣርእዮም።
This may also lead to post-intensive care syndrome following recovery.
እዚ ድማ ድሕሪ ምሕዋይ፣ ናብ ድሕሪ-ጽኑዕ ክትትል ሲንድረም ከምርሕ ይኽእል እዩ።
As of March 2020, it was unknown if past infection provides effective and long-term immunity in people who recover from the disease.
ስጋብ ማርች 2020፣ ዝሓለፉ ረኽሲታት ንጡፍን ናይ ነዊሕ ግዘን ናይ ሰብነት ሕማም ናይ ምክልኻል ዓቕሚ ክፈጥሩ ይኽኣሉ ኣይኽኣሉ ኣይፍለጥን እዩ።
Immunity is seen as likely, based on the behaviour of other coronaviruses, but cases in which recovery from COVID-19 have been followed by positive tests for coronavirus at a later date have been reported.
በቶም ካልኦት ኮሮናቫይረሳት ባህርይ መሰረት ዝገበሩ፣ በዚ ሕማም ዘይምጥቓዕ ተኸእሎታት ኣለዉ እዮም፣ ካብ ኮቨድ-19 ዝሓወዩ ጉዳያት ለበዳ ድሕሪ ግዘ ብ ናይ ኮረናቫይረስ ፖዘቲቭ ውጽኢት ዝተዓጀቡ ምዃኖም ዘርእዩ ጸብጻባት ወጺኦም እዮም።
These cases are believed to be worsening of a lingering infection rather than re-infection.
እዞም ኬዛት ናይ ኣብ ውሽጢ ዝጸንሐ ረኽሲ ምግዳድ እምበር ዳግም በቲ ረኽሲ ምትሓዝ ኣይኮኑን ተባሂሉ ይእመን።
The virus is thought to be natural and have an animal origin, through spillover infection.
እዚ ቫይረስ ተፈጥሮኣዊን ብመንገዲ ካብኡ ዝወሓዘ ረኽሲ ናይ እንስሳ መበቆል ኣለዎ ተባሂሉ ይሕሰብ።
The actual origin is unknown, but by December 2019 the spread of infection was almost entirely driven by human-to-human transmission.
ትኽክለኛ መበቆሉ ኣይፍለጥን፣ ኣብ ዲሰምበር 2019 ግን ናይ እቲ ረኽሲ ዝርጋሐ ዳርጋ ሙሉእ ብሙሉእ ካብ ሰብ ናብ ሰብ ዝተመሓላለፈ እዩ።
A study of the first 41 cases of confirmed COVID-19, published in January 2020 in The Lancet, revealed the earliest date of onset of symptoms as 1 December 2019.
ኣብ ጃንዋሪ 2020 ኣብ The Lancet ዝተሓተመ ኣብቶም ናይ መጀመርያ ዝተረጋጋጹ 41 ናይ ኮቪድ -19 ጉዳያት ለበዳ ዝተገበረ መጽናዕቲ፣ ጀሚሩ ዘሎ ናይ እቶም ምልክታት ዝተርኣዩሉ መጀመሪ ዕለት 1 ዲሰምበር 2019 ከም ዝኾነ ኣርእዮም።
Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019.
ካብ WHO ዝወጹ ዕላዊ ሕታማት ነቶም ቀዲሞም ዝተርኣዩ ምልክታት ኣብ 8 ዲሰምበር 2019 ጸብጺቦም እዮም።
Several measures are commonly used to quantify mortality.
ናይ ሞት በዝሒ ንምቑጻር ብዙሓት ስጉምቲታት ኣለዉ።
These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since initial outbreak and population characteristics such as age, sex and overall health.
እዞም ቁጽሪታት እዚኦም በቢ ክልሉን በቢ ግዜኡን ይፈላለዩ እዮም፣ ብ ናይ ምርመራ በዝሒ፣ ናይ ስርዓት ጥዕና ክንክን ጽፈት፣ ናይ ሕክምና መማረጺታት፣ ካብ እቲ ናይ መጀመርታ ለበዳ ዘጋጠመሉ ግዘ ዘሎ ግዘን ናይ እቲ በዝሒ ህዝቢ ባህርያትን ንኣብነት ከም ዕድመ፣ ጾታን ሓፈሻዊ ጥዕናንን ይጽሎ እዩ።
In late 2019, WHO assigned the emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection.The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval.
ኣብ 2019 መወዳእታታት፣ WHO ናይ ሃንደበታዊ ICD-10 ሕማም ኮዳት ሂቡ፣ U07.1 ንካብ ብ ቤተ ፈተነ ዝተረጋገጹ ናይ SARS-CoV-2 ረኽሲ ዘጋጠመ ሞት፣ U07.2 ድማ ብዘይ ናይ ቤተ ፈተነ ዝተረጋገጸ ናይ SARS-CoV-2 ረኽሲ ብክሊኒካላዊ ወይ ኢፒደሞሎጂያዊ መንገዲ ብኮቪድ-19 ንዝሞቱ ሰባት። እዚ ካብ ሞት-ናብ- ጉዳያት ለበዳ ንጽጽራዊ መጠን ዝሞቱ ሰባት በዝሒ ብዝተረጋገጹ ጉዳያት ለበዳ ኣብ ዝተወሃበ ግዘ ክካፈል ከሎ ዝብል እዩ ዘርኢ።
Based on Johns Hopkins University statistics, the global death-to-case ratio is 6.9% (153,822/2,240,191) as of 17 April 2020.
ብመሰረት ናይ Johns Hopkins University ስታትስቲክስ፣ ካብ 17 ኣፕሪል 2020 ጀሚሩ፣ ዓለምለኻዊ ናይ ጉዳይት ለበዳ ሞት ንጽጽራዊ መጠን 6.9% (153,822/2,240,191) እዩ።
The number varies by region.Other measures include the case fatality rate (CFR), which reflects the percent of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percent of infected individuals (diagnosed and undiagnosed) who die from a disease.
እዚ ቁጽሪ በቢ ክልሉ ይፈላለ እዩ። ካልኦት ስጉምቲታት ናይ ኬዝ ሞት ሬት (CFR) የካትት፣ በቲ ሕማም ናይ ዝሞቱ ሰባት ሚእታዊ ዘንጸባርቕ፣ ናይቲ ረኽሲ ናይ ሞት ሬት (IFR) ሓዊሱ፣ ናይ ዝተለኸፉን በቲ ሕማም ናይ ዝሞቱን ሰባት ሚእታዊ የንጸባርቕ (ተመርመሩን ዘይተመርመሩን)።
These statistics are not time bound and follow a specific population from infection through case resolution.
እዞም ቁጽራዊ መረዳእታታት እዚኦም ብግዘ ዝተገደቡ ኣይኩኑን፣ ብዝሓወየ ጉዳይ ለበዳ ገለ በዝሒ ህዝቢ ይኽተል።ጉዳይ ለበዳ ኣነጺርካ ብምርኣይ ረኽሲ ዝርከብ በዝሒ ህዝቢ ዝስዕቡ እዮም።
While not all infected people develop antibodies, the presence of antibodies may provide information about how many people have been infected.
ኩሎም ዝተጠቕዑ ሰባት ሕማም ስለዘየማዕብሉ፣ ናይ ኣንቲቦዲታት ምህላው ብዛዕባ ክንደይ ሰባት ተኣኪቦም ዝብል ሓበሬታ ከቕርብ ይኽእል።
In the epicentre of the outbreak in Italy, Castiglione d'Adda, a small village of 4600, 80 (1.7%) are already dead.
ኣብ ጣልያን ናይ መጀመርታ ማዕከል እዚ ለበዳ ዝኾንት ግዝኣት ካብ 4600 ዝኾኑ ነበርቲ 80 (1.7%) ሞይቶም።
In Gangelt, the disease was spread by Carnival festivals, and spread to younger people, causing a relatively lower mortality, and not all COVID-19 deaths may have been formally classified as such.
ኣብ ጋንግለት፣ እቲ ሕማም ብናይ ካርኒቫል ፌስቲቫል ምኽንያት አዩ ተላቢዑ፣ ናብ መናእሰይ እዩ ድማ ክላባዕ ክኢሉ በዚ ምኽንያት ድማ ውሑድ ሞት እዩ ኣጋጢሙ፣ ኩሎም ናይ ኮቪድ-19 ሞት ድማ ከምዚ ተባሂሎም ክፍለዩ የብሎምን።
Furthermore, the German health system has not been overwhelmed.
ብተወሳኺ፣ ናይ ጀርመን ጥዕና ስርዓት ካብ ዓቕሙ ንላዕሊ ብዝኾነ ዋሕዚ ኣይተውሓጠን።
In the Netherlands, about 3% may have antibodies, as assessed from blood donors.
ኣብ ኔዘርላንድስ፣ ብመሰረት ኣብ ደም ለገስቲ ዝተገበረ ዳህሳስ 3% ዝኾኑ ኣንቲቦዲታት ክህልዎም ይኽእል እዩ።
69 (0.004% of the population) have been confirmed to have died from COVID-19.
69 ሰባት (0.004% ናይ እቲ በዝሒ ህዝቢ) ብኮቪድ-19 ከምዝሞተ ተረጋጊጹ ኣሎ።
The impact of the pandemic and its mortality rate are different for men and women.
ናይ እዚ ለበዳ እዚ ጽልዋን ናይ ሞት ንጽጽራዊ መጠኑን ኣብ ደቂ-ተባዕትዮን ደቂ-ኣንስትዮን ዝተፈላለየ እዩ።
Mortality is higher in men in studies conducted in China and Italy.
ብመሰረት ኣብ ቻይናን ጣልያንን ዝተገበረ መጽናዕቲ ናይ ሞት መጠን ኣብ ሰብኡት ይበዝሕ።
The highest risk for men is in their 50s, with the gap between men and women closing only at 90.
ሰብኡት ናይ እቲ ዝዓበየ ናይ ተጋላጽነ ዕድመኦም ኣብ 50 ታት ዓመቶም እዩ፣ ኣብ መንጎ ኣንስቲን ሰብኡትን ዘሎ ኣፈላላይ ድማ 90 ጥራሕ እዩ።
In China, the death rate was 2.8 percent for men and 1.7 percent for women.
ኣብ ቻይና፣ ናይ ሞት ንጽጽራዊ መጠን ንሰብኡት 2.8 ሚእታዊ እንትኸውን ንኣንስትዮ ድማ 1.7 ሚእታዊ እዩ።
The exact reasons for this sex-difference is not known, but genetic and behavioural factors could be a reason.
ናይ እዚ ጾታ ፍልልይ ትኽክለኛ ምኽንያቱ ኣይተፈለጠን፣ ናይ ዘርኡን ባህሪያውን ምኽንያታት ግን ክኾኑ ይኽእሉ እዮም።
Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.
ጾታ መሰረት ዝገበረ ናይ ሰበነት ሕማም ናይ ምክልኻል ኣፈላላያት፣ ኣብ ኣንስቲ ዘሎ ትሑት ሽፋን ምትካኽ፣ከም በዝሒ ደም ዝኣመሰሉ፣ በዝሒ ተደረብቲ ሕማማት ኣብ ሰብኡት ምብዝሖም፣ ንናይ ሰብኡት ብበዝሒ ሞት ንጽጽራዊ መጠን እጃም ኣበርኪቱ ክኸውን ይኽእል እዩ።
In Europe, 57% of the infected individuals were men and 72% of those died with COVID-19 were men.
ኣብ ኣውሮፓ፣ 57% ዝተለኸፉ ውልቀ ሰባት ሰብኡት እንትኾኑ 72% ናይ ብኮቪድ-19 ዝሞቱ ሰባት እውን ሰብኡት እዮም።
As of April 2020, the US government is not tracking sex-related data of COVID-19 infections.
ካብ ኣፕሪል 2020 ጀሚሩ፣ ናይ ኣሜሪካ መንግስቲ ምስ ጾታ ዝተተሓሓዙ ናይ ኮቪድ-19 ረኽሲታት ሓበሬታ ኣይከታተልን እዩ ዘሎ።
Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.
መጽናዕቲታት ቫይራል ሕማማት ከም ኢቦላ፣ HIV፣ ኢንፍሉዌንዛን SARS ንሰብኡትን ኣንስቲን ብዝተፈላለዩ መገዲ እዮም ዘጥቅዑ።
A higher percentage of health workers, particularly nurses, are women, and they have a higher chance of being exposed to the virus.
ልዑል ክፋል ናይ ጥዕና ሰራሕተኛታት፣ ብፍላይ ነርስታት፣ ደቂ ኣንስትዮ እየን፣ ናብ እቲ ቫይረስ ናይ ምቅላዕ ዕድሎም ድማ ልዑል እዩ።
The World Health Organization announced on 11 February 2020 that the official name of the disease would be "COVID-19".
ትካል ዓለም ጥዕና ኣብ ጥሪ 11,2020 ናይዚ ሕማም መጸውዒ ሽም "COVID-19" እዩ ኢሉ ኣዊጁ።
WHO chief Tedros Adhanom Ghebreyesus explained that CO stands for corona, VI for virus, D for disease, and 19 for when the outbreak was first identified: 31 December 2019.
ናይ ውደብ ጥዕና ዓለም(WHO) ሓላፊ ቴድሮስ ኣድሓኖም ገብረየሱስ፣ CO ኮሮና ዝውክል እንትኸውን ፣ VI ድማ ናይ ቫይረስ፣ D ድማ ሕማም ማለት ከምዝኾነ ኣብራህሪሆም፣ 19 ድማ እቲ ለበዳ መጀመርያ ዝተፈለጠሉ ዓመተ ምህረት የመላኽት: 31 ዲሰምበር 2019።
The name had been chosen to avoid references to a specific geographical location (e.g. China), animal species or group of people, in line with international recommendations for naming aimed at preventing stigmatisation.The virus that causes COVID-19 is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
እዚ ሽም ናይ እንስሳት ዓሌት ወይ ናይ ሰባት ጉጅለ፣ ሽም እንተውጽእ ኣድልዎ ኣብ ምክልኻል ዝዓለመ ክኸውን ዝብል ዓለምለኻዊ ምኽሪታት መሰረት ብምግባር ንፍሉይ ጂኦግራፊያዊ ቦታ ከይገልጽ ተባሂሉ እዩ ተዋሂብዎ (ንኣብነት፣ ቻይና) ። እቲ ኮቪድ-19 ዘስዕብ ቫይረስ ከቢድ ህጹጽ ናይ ስርዓተ ምትንፋስ ሲንድረም ኮሮናቫይረስ 2 (SARS-CoV-2) እዩ ዝበሃል።
The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.
WHO(ውድብ ጥዕና ዓለም) ብተወሳኺ ን"ናይ ኮቪድ -19 ቫይረስ" ን "ንኮቪድ-19 ዘምጽእን ቫይረስ" ዝብሉ ኣገላልጻታት ኣብ ህዝባዊ መግለጺታት ይጠቀመሎም ኣሎ።
Both the disease and virus are commonly referred to as "coronavirus".
ክልቲኦም እቲ ሕማምን እቲ ቫይረስን "ኮሮናቫይረስ" ተባሂሎም ይጽውዑ።
During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus".
ኣብ ናይ ውሃን፣ቻይና ናይ መጀመርያ ለበዳ ግዘ፣ እቲ ሕማምን ቫይረስን ብሓባር "ኮሮናቫይረስ" ከምኡውን "ውሃን ኮሮናቫይረስ " ተባሂሎም ይጽውዑ ነይሮም።
In January 2020, WHO recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease in accordance with 2015 guidance against using locations in disease and virus names.
ኣብ ጃንዋሪ 2020፣ ነቲ ናይ 2015 ኣብ ናይ እቲ ሕማምን ቫይረስን ሽም ቦታታት ምጥቃም ዘይፍቀድ እዩ ዝብል መምርሒ መሰረት ብምግባር፣ ውደብ ጥዕና ዓለም(WHO) ናይ 2019-nCov ን 2019-nCoV ከቢድ ናይ ስርዓተ ምስትንፋስ ሕማም ናይ እቲ ቫይረስን ሕማም ዝብሉ ግዜያዊ መጸውዒ ሽማት ክኾኑ መኺሩ ኣሎ።
The official names COVID-19 and SARS-CoV-2 were issued on 11 February 2020.
ናይ ኮቪድ-19 ን SARS-CoV-2 ን ዕላዊ ሽማት ኣብ 11 ፌብሩዋሪ 2020 እዮም ዕላዊ ተገይሮም።
Due to capacity limitations in the standard supply chains, some digital manufacturers are printing healthcare material such as nasal swabs and ventilator parts.
ብሰንኪ ኣብ እቲ ደረጃኡ ዝሓለወ ናይ ኣቕርቦት ሰንሰለት ዘሎ ናይ ዓቕሚ ሕጽረት፣ ገለ ዲጂታል መፍረይቲ ከም ናይ ኣፍንጫ ስዋባትን ናይ ቨንትሌተር ኣካላትን ዝበሉ ናይ ጥዕና ናውቲታት ኣብ ምሕታም ይርከቡ።
In one example, when an Italian hospital urgently required a ventilator valve, and the supplier was unable to deliver in the timescale required, a local startup reverse-engineered and printed the required 100 valves overnight.
ኣብ ሓደ ኣብነት፣ ናይ ጣልያን ሆስፒታል ብህጹጽ ቬንትሌተር ቫልቭ ከድልዮ ከሎ፣ እቲ መቕረባይ ድማ ኣብቲ ዝተበሃሎ ናይ ግዘ ገደብ ከቕርብ ብዘይምኽኣሉ፣ ናይ እቲ ከባቢ ጀማሪ ብግልባጥ ምህንድስና እቲ ዘድሊ 100 ቫልቭ ኣብ ሓደ ለይቲ ሰሪሑ ወዲኡ።
After the initial outbreak of COVID-19, conspiracy theories, misinformation and disinformation emerged regarding the origin, scale, prevention, treatment and other aspects of the disease and rapidly spread online.
ድሕሪ ናይ መጀመርያ ናይ ኮቪድ -19 ለበዳ፣ ብዛዕባ መበቆሉ፣ ስኬሉ፣ ምክልኻል መገዱ፣ መድሓኒትን ካልኦት ናይ እቲ ሕማም ኣካላትን ናይ ሴራ ስነ-ሓሳባት፣ ጌጋ ሓበሬታታትን ናይ ሓሶት ሓበሬታታትን ብቕልጡፍ ኣብ ኦንላይን ክሰራጨዉ ጸኒሖም።
Humans appear to be capable of spreading the virus to some other animals.
ደቂ ሰባት ነቲ ቫይረስ ናብ እንስሳት ከመሓላልፍዎ ይኽእሉ እዮም።
The study failed to find evidence of viral replication in pigs, ducks, and chickens.
እዚ ቫይረስ ኣብ ሓሰማ፣ ማይ ደርሆን ምብዛሕ ንምኽኣሉ እቲ መጽናዕቲ መረዳእታ ክረክብ ኣይከኣለን።
No medications or vaccine is approved to treat the disease.
ነዚ ሕማም ንምሕካም ዝተፈቐደ መድሓኒት ኮነ ክትባት የለን።
International research on vaccines and medicines in COVID-19 are underway by government organisations, academic groups and industry researchers.
ኣብ ኮቪድ-19 ዝግበሩ ናይ ክትባታትን መድሓታትን ዓለምለኻዊ መጽናዕቲ ብመንግስታዊ ትካላትን፣ ኣካዳሚካዊ ጉጅለታትን ናይ ኢንዳስትሪ መጽናዕቲን እንዳተኻየደ ይርከብ።
In March, the World Health Organization initiated the "SOLIDARITY Trial" to assess treatment effects of four existing antiviral compounds with the most promise of efficacy.
ኣብ ማርች፣ ናይ ዓለም ጥዕና ድርጅት ናይ "SOLIDARITY Trial" ናይዞም ዘለዉ ኣርባዕተ ጸረ ቫይረስ ኮምፓውንድታት ልዑል ተስፋ ይህቡ ምስ ምህላዎም ፈተነታት ጀሚሩ ኣሎ።
There is no available vaccine, but various agencies are actively developing vaccine candidates.
ክትባተ የብሉን ግን፣ ዝተፈላለዩ ኤጀንሲታት ናይ ክትባት ሕጹያት ብንቕሓት የማዕብሉ ኣለዉ።
Previous work on SARS-CoV is being utilised because SARS-CoV and SARS-CoV-2 both use the ACE2 receptor to enter human cells.
ቅድም ክብል ኣብ SARS-CoV ዝተኻየዱ ስራሕቲ፣ ኣብ ጥቕሚ ይውዕሉ ኣለው እዚ ድማ SARS-CoV ን SARS-CoV-2ን ክልቲኦም ናብ ናይ ሰብ ዋህዮ ንምእታው ACE2 ተቐባሊ ዝጥቀሙ ብምዃኖም እዩ።
There are three vaccination strategies being investigated.
ሰለስተ ናይ ክትባት ሜላታት ኣብ ምርመረ ይርከቡ።
First, researchers aim to build a whole virus vaccine.
መጀመርታ፣ ተመራመርቲ ሙሉእ ናይ ቫይረስ ክትባት ክሰርሑ እዮም ዝፍትኑ ዘለዉ።
The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID-19.
ከምዚ ዓይነት ቫይረስ ምጥቃም፣ ዘይንጡፍ ይኹን ምውት፣ ናይ ደቂ ሰብ ሰውነት ነዚ ሓድሽ ኮቪድ-19 ቫይረስ ናይ ምክልኻል ዓቕሚ ንምምዕባል ዕላማ ዝገበረ እዩ።
A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus.
ካልኣይ ስትራቴጂ፣ ክፋል ዩኒት ክትባታት፣ነቲ ናይ ሰበነት ሕማም ናይ ምክልኻል ስርዓት ን ዝተወሰኑ ናይ እቲ ቫይረስ ናይ ዩኒት ክፋላት ክነቓቓሕ ንምግባር ዝዓለመ እዩ።
In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor.
ኣብ እዚ ናይ SARS-CoV-2 ጉዳይ ለበዳ፣ ከምዚ ዓይነት መጽናዕቲ ኣብ S-spike ፕሮቲን ነቲ ቫይረስ ናብ እቲ ACE2 ኢንዛይም ተቐባሊ ንክኣቱ ዝሕግዝ ትኹረት ዝገበረ እዩ።
A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination).
እቲ ሳልሳይ ሜላ ድማ ናይ ኒዩክሊክ ኣሲድ ክትባታት እዮም (DNA ወይ RNA ክትባታት፣ ሓድሽ ናይ ክትባት ምፍጣር ቴክኒክ)።
Experimental vaccines from any of these strategies would have to be tested for safety and efficacy.On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle.
ካብዞም ዘዴታት ውሽጢ ናይ ሙከራ ኽትባት ንደሕንነትን ሓቅነትን ብፈተነታት ክሓልፉ ኣለዎም። ብኣቆጻጽራ ኣውሮፓ ኣብ መጋቢት 16፣ 2020 እቲ ናይ መጀመርታ ክትባት ብኣርባዕተ ፈቓደኛ ሰባት ኣብ ሲያትል ተጀሚሩ።
The vaccine contains a harmless genetic code copied from the virus that causes the disease.Antibody dependent enhancement has been suggested as a potential challenge for vaccine development for SARS-COV-2, but this is controversial.
እዚ ክትባትካብ እቲ ነቲ ሕማም ዘስዕብ ቫይረስ ዝቐድሖ ዘይጎድእ ጀኒቲክ ኮድ ኣለዎ። ብኣንቲቦዲ ዝድገፍ ምምሕያሽ ኣብ ናይ SARS-COV-2 ክትባት ምዕባለ ዝተመኸረ ነገር እዩ፣ እንተኾነ ግን እዚ እውን መዘራረቢ እዩ።
There are more than 300 active clinical trials underway as of April 2020.
ካብ ኣፐሪል 2020 ጀሚሮም፣ ልዕሊ 300 ንጡፋት ክሊኒካል ፈተነታት ይካየዱ ኣለዉ እዮም።
Seven trials were evaluating already approved treatments for malaria, including four studies on hydroxychloroquine or chloroquine.
ኣብ hydroxychloroquine(ሃይድሮክሲክሎሮኲን) ወይ chloroquine(ክሎሮኲን) ዝገበሩ መጽናዕቲታት ሓዊሱ፣ ሸውዓተ ፈተነታት ዓሶ ንምሕካም ፈቓድ ዘለዎም መድሓኒታት ይፍትኑ ነይሮም።
Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April.
ዳግም ንካልእ ዐላማ ዝተዳለወ ጸረ ቫይረስ መድሓኒት መብዛሕትኡ ናይ ቻይና መጽናዕቲ ዝሓዘ እዩ፣ ምስ ትሽዓተ ፌዝ III ናይ remdesivir ፈተነታት ኣብ ዝተፈላለዩ ሃገራት ኣብ ናይ ኣፕሪል መወዳእታ ዝወጸ ሪፖርት ከምዘርእዮ።
A dynamic review of clinical development for COVID-19 vaccine and drug candidates was in place, as of April 2020.Several existing antiviral medications are being evaluated for treatment of COVID-19, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir combined with interferon beta.
ካብ ኣፕሪል 2020 ጀሚሩ ናይ ኮቪድ-19 ክትባት ምዕባለን ዝተመረጹ መድሓኒታትን ዓብዪ ገምጋም ተኻይዱ እዩ ። remdesivir(ሬምደስቪር)፣ chloroquine(ክሎሮኲን) ን hydroxychloroquine(ሃይድሮክስይክሎሮኲን) ን፣ lopinavir/ritonavir(ሎፒናቪር/ሪቶናቪር) ከምኡውን lopinavir/ritonavir(ሎፒናቪር/ሪቶናቪር) ምስ interferon beta(ኢንተርፈሮን ቤታ) ሓዊሱ ዝተፈላለዩ ጸረ- ቫይረስ መድሓኒታት ንናይ ኮቪድ-19 ምርመራ ገምጋም ይግበሮም ኣሎ ።
There is tentative evidence for efficacy by remdesivir, as of March 2020.
ካብ ማርች 2020 ጀሚሩ ናይ remdesivir ብቕዑነት ዘርኢ ዝተወሰነ መረዳእታ ኣሎ።
Clinical improvement was observed in patients treated with compassionate-use remdesivir.
ክሊኒካዊ ምምሕያሻት ኣብ ቀሊል ናይ remdesivir(ሬምደስቪር) መድሓኒት ኣብ ዝተፈተነሎም ሰባት ተራእዩ እዩ።
Phase III clinical trials are being conducted in the US, China and Italy.Chloroquine, previously used to treat malaria, was studied in China in February 2020, with preliminary results.
ፌዝ III ክሊኒካዊ ፈተነታት ኣብ US፣ ቻይናን ጣልያንን ይካየዱ ኣለዉ። Chloroquine፣ ዓሶ ንምሕካም ዝጠቅም ዝነበረ መድሓኒት፣ ኣብ ቻይና መጽናዕቲ ተገይሩሉ ኣብ ፌብሩዋሪ 2020፣ናይ መጀመርታ ውጽኢት ድማ ኣርእዩ።
However, there are calls for peer review of the research.
እንተኾነ ግን፣ ናይ እቲ መጽናዕቲ ገምጋም ኣድለይቲ እዮም።
Korean and Chinese Health Authorities recommend the use of chloroquine.
ናይ ኮርያን ቻይናን ናይ ጥዕና ሓለፍቲ chloroquine ምጠቃም ይመኽሩ።
However, the Wuhan Institute of Virology, while recommending a daily dose of one gram, notes that twice that dose is highly dangerous and could be lethal.
እንተኾነ ግን፣ Wuhan Institute of Virology (ናይ ውሃን ቫይሮሎጂ ትካል)፣ ናይ ሓደ ግራም መዓልታዊ ዶዝ ዝመክር እንትኸውን፣ ናይ እዚ ዶዝ ክልተ ምውሳድ ግን ኣዝዩ ሓደገኛ ከምዝኾነን ክቐትል እውን ከምዝኽእል ሓቢሩ እዩ።
On 28 March 2020, the FDA issued an emergency use authorisation for hydroxychloroquine and chloroquine at the discretion of physicians treating people with COVID-19.The Chinese 7th edition guidelines also include interferon, ribavirin or umifenovir for use against COVID-19.
ኣብ 28 መጋቢት 2020፣ FDA ናይ hydroxychloroquineን chloroquineን ንኮቪድ-19 ንታሓከምቲ ዝሐክሙ ዘለዉ ሓካይም ኣብ እዋን ህጹጽ ረድኤት ክጥቀሙ ኣፍቂዱ። እዚ ናይ ቻይና 7ይ ሕታም መምርሒ interferon፣ ribavirin ወይ umifenovir እውን ኣንጻር ኮቪድ-19 ምጥቃም እውን ዘካተተ እዩ።
Preliminary data indicate that high doses of ribavirin are necessary to inhibit SARS-CoV-2 in vitro.
ናይ መጀምርታ መረዳእታ ከምዝሕብሮ ልዑል ናይ ribavirin መጠን SARS-CoV-2 ብቪትሮን ንምግታዕ ኣድላዪ እዩ።
Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.Studies have demonstrated that initial spike protein priming by transmembrane protease serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2 via interaction with the ACE2 receptor.
Nitazoxanide(ኒታዞሳናይድ) ድሕሪ ኣብ ናይ SARS-CoV-2 ምውጋድ ትሑት ጻዕቒ ምርኣዩ፣ ንተወሳኺ ኣብ vivo ዝግበር መጽናዕቲ ተመኺሩ እዩ። መጽናዕቲታት ናይ መጀመርያ ስፓይክ ፕሮቲናት ብትራንስመምብሬን ፕሮቴዝ ሲሪን 2 (TMPRSS2) ዝተተሓሓዙ ን SARS-CoV-2 ምስ ACE2 ተቐበልቲ ብምትእትታው ንክኣቱ ወሰንቲ እዮም።
The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.Oseltamivir does not inhibit SARS-CoV-2 in vitro and has no known role in COVID-19 treatment.
ናይ chloroquine ን hydroxychloroquine ን ምስ azithromycinን ካብኡ ወጻኢ ዝተገበሩ መጽናዕቲታት ብዘይ ተወሳኺ መጽናዕቲ ናይ ሕክምና ማሕበረ ሰብ ክጥቀመሎም ዘይከኣለሉ ምኽንያት ዓበይቲ ግድፈታት ዘለዉዎም ብምዃኖም እዩ። Oseltamivir ን SARS-CoV-2 ኢን ቪትሮ ኣይግድብን ኣብ ናይ ኮቪድ-19 ሕክምና ድማ ዝኾነ ዓይነት እጃም የብሉን።
Cytokine storm can be a complication in the later stages of severe COVID-19.
Cytokine storm ናይ ከቢድ ኮቪድ-19 ናይ መጨረሻ ከባቢ ጎድናዊ ጽልዋ እዩ።
There is evidence that hydroxychloroquine may have anti-cytokine storm properties.Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.
hydroxychloroquine ጸረ-ሳይቶኪን ስቶርም ባህሪታት ከምዘለዎ መረጋገጺ ኣሎ።Tocilizumab ኣብ ናይ ቻይና ብሄራዊ ናይ ንእሽተይ መጽናዕቲ ድሕሪ ምክያዱ ኣብ ናይ ሕክምና መምርሒኡ ተጠቓሊሉ እዩ።
It is undergoing a phase 2 non randomised test at the national level in Italy after showing positive results in people with severe disease.
ኣብ ከቢድ ሕማም ዘለዎም ሰባት ፖዘቲቭ ውጽኢታት ድሕሪ ምርኣይ ብ ብሄራዊ ደረጃ ኣብ ጣልያ ናይ ፌዝ 2 ኣጋጣሚ ዘይኮነ ፈተነ ይካየድ ኣሎ።
Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people.
ምስ ሴረም ፌሪቲን ዝተሓወሰ ሳይቶካይን ስቶርም ንምፍላይ ዝግበር ናይ ደም ምርመራ ነዞም ኣብ ገለ ሰባት ናይ ሞቶም ምኽንያት እዮም ተባሂሎም ዝእመኑ ከምዚኦም ዝበሉ ምዕባለታት ጽልዋ ንምቕናስ ተባሂሉ እዩ ተኻይዱ።
The interleukin-6 receptor antagonist was approved by the FDA based on retrospective case studies for treatment of steroid refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017.
ብ መሰረት ኣብ ሕሉፍ ዝተርኣየ ጉዳይ ንናይ ብዘተፈላለዩ ምኽንያታት ዝፍጠሩ ናይ steroid refractory cytokine ዝሰደዱ ሲንድረማት መሐከሚ interleukin-6 receptor antagonist ብ FDA ተፈቒዱ እዩ፣ CAR T ናይ ዋህየ ሕክምና፣ ኣብ 2017።
To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS.
ክሳብ ሕዚ፣ ናይ ኣጋጣሚ ዝኾነ፣ ቁጽጽር ዝተገበሮመረዳእታ tocilizumab ብቑዕ ናይ CRS ከምዝኾነ ዘርኢ የለን።
Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of passive immunisation.
ብ ካብ ኮቪደ-19 ዝሓወዩ ሰባት ናይ ሕማም ምክልኻል ዓቕሚ ዝፈረየ ዘተጻረየን ዝሓፈሰን ኣንቲቦዲ ንዘድልዮም ሰባት ምምሕልላ፣ ከም ክትባት ዘይኮነ ግን ውሽጣዊ ናይ ሕማም ምክልኻል ዓቕሚ ዝሃንጽ ተባሂሉ መጽናዕቲ እንዳተኻየደሉ ይርከብ።
This strategy was tried for SARS with inconclusive results.
እዚ ሜላ እዚ ኣብ SARS ተፈቲኑ ዘየዕግብ ውጽኢት ሂቡ እዩ።
Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2.
ናይ ቫይረስ ኒውትራላይዜሽን ማለት ፓሲቭ ኣንቲቦዲ ሕክምና ኣንጻር SARS-CoV-2 ንምክልኻል ክገብሮ ዝኽእሎ ኣካይዳ እዩ።
Other mechanisms however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible.
ካልኦት ሜላታት ግን፣ ከም ኣንቲቦዲ -መሰረት ዝገበሩ ሴሉላር ሳይቶክሲሲቲን/ወይ ፋጎሳይቶሲስ፣ እውን ክግበሩ ይኽእሉ እዮም።
Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.
ካልኦት ድሑራት ናይ ኣንቲቦዲ ሕክምናታት፣ ንኣብነት፣ ዝተመረቱ ሞኖክሎናል ኣንቲቦዲታት ምጥቃም፣ ኣብ ምምዕባል ይርከብ።
Production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.
ናይ ኮንቨልሰት ሴረም ምፍራይ፣ ካብ ካብቲ ሕማም ዝሓወዩ ሰባት ዝተወሰደ ደም ፈሳሲ ክፋል ዝሓዘ እንትኸውን ናይ እቲ ቫይረስ ኣንቲቦዲ ድማ ዝሓዘ እዩ፣ ንቅልጡፍ ኣድማዒነት ድማ ክጠቅም ይኽእል እዩ።
Coronavirus diseases, a group of closely related syndromes
ናይ ኮሮናቫይረስ ሕማም፣ ብቐረባ ዝተተሓሓዙ ሲንድሮማት ጉጅለ
Li Wenliang, a doctor at Central Hospital of Wuhan, who later contracted and died of COVID-19 after raising awareness of the spread of the virus.
ሊ ወንሊያንግ፣ ናይ ውሃን ማእኸላይ ሆስፒታል ዶክተር፣ብዛዕባ ኮቪድ-19 ቫይረስ ግንዛበ ፈጢሩ፣ ድሕሪ ግዘ ድማ በቲ ቫይረስ ተታሒዙ ዝሞተ እዩ።